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Erectile dysfunction (ED) is a prevalent form of male sexual dysfunction. Phosphodiesterase type 5
(PDE5) inhibitor is the ﬁrst-line treatment for ED. Numerous well-designed and -conducted clinical trials
and postmarketing studies have established the safety and efﬁcacy of PDE5 inhibitors for the treatment
of ED. Ever since the ﬁrst approval of sildenaﬁl in 1998, PDE5 inhibitors have had several advances in
their clinical use. More new agents with different pharmacokinetic proﬁles and new formulations were
marketed. Conventional on-demand administration expanded to daily dosing. These advances provide
more ﬂexibility in clinical treatment of ED for patients and physicians. Moreover, clinical indications of
PDE5 inhibitors extend from treatment of ED to pulmonary arterial hypertension and signs and symp-
toms of benign prostatic hyperplasia because of the distribution of PDE5 enzyme in human organs and
tissues. The evolution of PDE5 inhibitors heralds a remarkable medical history from bench to clinical
practice.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The phosphodiesterase (PDE) system had been identiﬁed for
many years but was not initially considered to play a signiﬁcant
physiological role in humans. The system includes 11 families
with > 50 isoforms and is widely distributed in human organs
and tissues.1 PDEs catalyze breakdown of cyclic GMP or cyclic
AMP, so-called second messengers, which in turn are converted
to biologically inactive monophosphates, resulting in termina-
tion of their physiological functions. PDE type 5 was ﬁrst
discovered by Francis and Corbin2 in 1980 and is enriched in the
corpus cavernosum compared with other PDE enzymes. PDE5
enzyme is a homodimer containing two identical subunits that
each consists of regulatory and catalytic domains (Figure 1). The
catalytic domain is the direct target of PDE5 inhibitors. The
regulatory domain contains allosteric cGMP-binding sites and a
phosphorylation site for negative feedback regulation of the
enzyme.3t of Medical Education and
Tachung 1st Road, Kaohsiung
gmail.com.
ociation. Published by Elsevier Ta2. Serendipity: From angina to erectile dysfunction
The discovery of PDE5 inhibitors for treatment of erectile
dysfunction (ED) is a remarkable case of serendipity. Before the
advent of PDE5 inhibitors, treatment choices for ED were limited to
penile implant and intracavernosal injection. The invasive nature
and fear of injection prevented them from widespread acceptance
by patients and physicians. Only a small portion of ED patients ever
beneﬁted from such treatments. In 1989, compound UK-92,480,
now better known as sildenaﬁl citrate, was ﬁrst synthesized and
tested in Pﬁzer's laboratories.4 Preliminary data showed that
inhibiting PDE5 might produce beneﬁcial effects of decreased
vascular resistance and reduced platelet aggregation. Clinical
studies on sildenaﬁl citrate 50 mg, three times daily, as an anti-
angina agent began in 1991 in England but the clinical effects
were mild. The untoward side effect of penile erection hinted to
scientists that PDE5 and cGMP might play a role in penile erection
and the potential of sildenaﬁl as a treatment for ED. Occupation of
the catalytic domain by PDE5 inhibitor, a competitive inhibitor,
blocks the access of cGMP and its breakdown, which increases the
concentration of cGMP in tissues. The Ignarro group reported that
penile erection was mediated through elevation of NO-induced
cGMP in corpus cavernosum smooth muscle of rabbits in 1990.5
Subsequent research provided insights into the biological andiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Figure 1. Structure of PDE5 enzyme shows two identical submits and each contains a
catalytic and a regulatory domain. PDE5 inhibitors target the catalytic domain. The
regular domain in the amino-terminal protein contains a phosphorylation site and two
allosteric cGMP-binding sites (a and b). PDE5 ¼ phosphodiesterase type 5; cGMP ¼
cyclic guanosine manuscript; p ¼ phosphate; S ¼ serine-102.
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vascular smooth muscle relaxation and vasodilation, and penile
erection. Accumulation of cGMP in smooth muscle cells of the
penile corpus cavernosum after taking a PDE5 inhibitor results in
improvement of erectile rigidity and helps management in men
with erectile impairment.
The ﬁrst pivotal study of sildenaﬁl for ED treatment consisted of
a two-phase crossover study.6 In the ﬁrst phase, patients were
randomized to sildenaﬁl 10 mg, 25 mg, or 50 mg or placebo, and in
the second phase, patients were randomized to sildenaﬁl 25 mg or
placebo for 7 days. Compared with placebo, taking sildenaﬁl with
sexual stimulation signiﬁcantly improved penile erection in men
with ED as monitored by nocturnal penile erection device.6 A
pivotal Phase III study of sildenaﬁl was published in 1998,7 inwhich
the efﬁcacy was assessed by a validated 15-item self-reported
questionnaire, the International Index of Erectile Function (IIEF).8
Sildenaﬁl (Viagra; Pﬁzer, New York, NY, USA) was the ﬁrst PDE5
inhibitor approved for treatment of ED in the US in 1998 and
Taiwan in 1999. Tadalaﬁl (Cialis; Lilly ICOS, Indiana, IN, USA) and
vardenaﬁl (Levitra; Bayer AG, Leverkusen, Germany) were
approved in Taiwan in 2003. Pharmacotherapy with PDE5 in-
hibitors has the advantages of easy administration and good
effectiveness with minimal side effects, which brought a revolu-
tionary change in the treatment of ED.9
3. Safety and efﬁcacy of PDE5 inhibitors
PDE5 inhibitors are probably the best studied in well-designed
clinical trials on the planet.10 Most currently available evidencefor efﬁcacy and safety of PDE5 inhibitors for the treatment of ED are
attributed to sildenaﬁl, tadalaﬁl, and vardenaﬁl. Numerous well-
conducted randomized placebo-control trials and postmarketing
studies have established their safety and efﬁcacy in the treatment
of ED.9,11,12 Oral PDE5 inhibitors are generally recommended for
ﬁrst-line therapy unless they have contraindications for clinical use.
A tremendous growth of utilization data of PDE5 inhibitors in
global and Taiwan markets was reported from 1999 to 2011.13 The
success of oral pharmacotherapy for ED culminated in the intro-
duction of more agents, advent of new formulations and routes of
administration, and new clinical indications for PDE5 inhibitors in
the past decade (Table 1).
PDE5 inhibitors can be administered orally at concentrations
sufﬁcient to inhibit PDE5 with minimal serious side effects related
to inhibition of other PDEs or non-PDE targets. The most commonly
reported treatment-emergent adverse events include headache,
ﬂushing, and gastrointestinal upset that are related to the distri-
bution of PDE enzyme, and are transient and mild in severity.9
However, rare serious toxicity has been reported in association
with PDE5 inhibitor use, including hearing loss, nonarteritic ante-
rior ischemic optic neuropathy, and priapism.14 A critical analysis
and review of the literature demonstrates no conclusive evidence
to indicate a direct causeeeffect relationship between PDE5 in-
hibitor use and vision-threatening ocular events.15 Likewise, no
causal link could be established between sildenaﬁl and cardiovas-
cular events or any new safety risk relating to cardiovascular events
and those rare toxicities.10
4. New PDE5 inhibitors
The success of the ﬁrst generation of PDE5 inhibitors has stim-
ulated the development and marketing of more new PDE5 in-
hibitors (Table 1) that provide greater ﬂexibility for physicians and
patients in clinical use. Udenaﬁl16 (Zydena; Dong-A Pharmaceutical
Co., Seoul, Korea) has a relatively rapid onset [time to maximum
concentration (Tmax) ¼ 1e1.5 hours] and a long duration of action
(T1/2 ¼ 11e13 hours; Table 2), and can be used on demand or once
daily.17 To date, udenaﬁl is approved only in Korea, Russia, and the
Philippines. Avanaﬁl (Stendra or Spedra; Vivus, Mountain View, CA,
USA) has the advantage of rapid onset (Tmax 35minutes) and a short
half-life (< 1.5 hours)18 compared with other PDE5 inhibitors.
Avanaﬁl was approved by the United States Federal Drug Admin-
istration (FDA) in 2012 and by the European Medicines Agency in
2013. Mirodenaﬁl (SK Chemicals Life Science, Seoul, South Korea) is
characterized by its selectivity toward PDE5 being 10-fold higher
than that of sildenaﬁl, whereas its inhibitory effects on other PDEs
were much lower than those of sildenaﬁl in preclinical studies.19
Mirodenaﬁl was approved in Korea in 2007.20
5. New formulation
The oral route of administration is the most convenient and
popular for most therapeutic agents. Conventional PDE5 inhibitors
are produced as solid ﬁlm-coated tablets and have to be swallowed
with water. Oral dispersible tablets (ODTs) provide a novel and an
attractive formulation, dissolving or disintegrating rapidly in the
oral cavity. Compared to conventional ﬁlm-coated tablets, ODT
formulation has several advantages, including rapid onset, easier
administration (without water), bypassing the gastrointestinal
tract and hepatic portal systems, and better patient compliance.21
ODTs have a palatable ﬂavor because of oral dissolving, avoiding a
bitter taste and a connection with taking a pill for sex.
Levitra ODT (10 mg) was the ﬁrst PDE5 inhibitor introduced in
ODT formulation with a minty taste in 2011. A pharmacokinetic
study demonstrated that taking vardenaﬁl ODT without water can
Table 1
Advances in the phosphodiesterase type 5 inhibitors in clinical use.
Variables Remarks (Agents approved)
Agents 1st generation: sildenaﬁl, tadalaﬁl, & vardenaﬁl
2nd generation: udenaﬁl, avanaﬁl, & mirodenaﬁl
Formulation Traditional: ﬁlm-coated (all agents)
New: orodispersible tablet (vardenaﬁl, sildenaﬁl, & mirodenaﬁl)
Dosing Traditional: on demand (all agents)
New: daily dosing (tadalaﬁl)
Indications 1. Erectile dysfunction (all the agents)
2. Pulmonary artery hypertension (sildenaﬁl & tadalaﬁl)
3. Lower urinary tract symptoms secondary to benign
prostatic hyperplasia (tadalaﬁl)
Table 2
Pharmacokinetics of the phosphodiesterase type 5 inhibitors.
Agents Cmax ng/mL Tmax (h) T1/2 (h)
Sildenaﬁl 100 mg 450 0.8 3e5
Tadalaﬁl 20 mg 378 2 17.5
Vardenaﬁl 20 mg 20.9 0.7e0.8 4e5
Udenaﬁl 100 mg 416.2 1e1.5 11e13
Avanaﬁl 100 mg 871 0.5e1.5 <1.5
Mirodenaﬁl 100 mg 373.4 1.25 2.5
Cmax ¼ maximum plasma concentration; Tmax time to reach Cmax; T1/2 ¼ half-life.
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concentrationetime curve, compared with ﬁlm-coated tablets in
men with ED.22 Integrated analyses of two pivotal trials of Levitra
ODT demonstrated its effectiveness and safety in men with ED and
its time to onset of action was comparable to that of ﬁlm-coated
tablets.23,24 Sildenaﬁl ODT (50 mg) with a lemon ﬂavor was intro-
duced in Taiwan in 2015. Pharmacokinetic studies showed no sig-
niﬁcant difference between sildenaﬁl ODTs and ﬁlm-coated
tablets.25,26 The study also showed that a high-fat meal reduced
absorption of ODT and therefore sildenaﬁl ODT should be taken on
an empty stomach.26 However, no study has been conducted to
prove whether ODT formulation is preferred over conventional
ﬁlm-coated formulation in clinical practice.
6. Route of administration
Sildenaﬁl was the ﬁrst drug designed for use only if necessary
(on demand), although initially it was designed to be taken three
times daily. ED patients have to take sildenaﬁl or vardenaﬁl 1 hour
before and tadalaﬁl 2 hours before sexual activity, considering the
onset and Tmax (Table 2). The therapeutic window may last for
12 hours for 100 mg sildenaﬁl,27 10 hours for 20 mg vardenaﬁl,28
and 36 hours for 20 mg tadalaﬁl,29 which is approximately two
times their half-life (Table 2). Taking a pill before sexual activity
does not necessarily represent successful sexual intercourse. Sexual
activity may be inﬂuenced by the behavioral complexity of sexual
intimacy, such as the communication and coordination around the
frequency, timing and initiation of sexual activity.30,31 A large
population survey in Eastern countries revealed that 50% of men
did not want to plan their sexual activity.32Table 3
Differences in clinical effect of phosphodiesterase type 5 inhibitors administered on dem
Variables On-demand administra
Time frame for sex Yes
Sexual frequency For all sexual frequenci
Incidence of treatment-emergent adverse effects Higher
Peak plasma concentration of agent Adequate
Treatment expenditure Relatively lower
Beneﬁcial effects on lower urinary tract symptoms IntermittentA longer duration of therapeutic window allows more sponta-
neity for sex and more time to look for the optimal moment for sex
than a shorter therapeutic window. Tadalaﬁl has the longest half-
life (17.5 hours) among the PDE5 inhibitors. The ﬁrst study of
daily dosing of tadalaﬁl 10 mg or 20 mg was conducted to salvage
previously unresponsive to on-demand tadalaﬁl and 60% of pa-
tients converted to responders.33 A pharmacokinetic study showed
that at the simulated steady state, tadalaﬁl 5 mg once daily pro-
vided plasma concentrations > 55 ng/mL, and ~90% enzyme inhi-
bition in vitro,34 which is similar to those observed 24 hours after
tadalaﬁl 20 mg two or three times weekly.35 An integrated analysis
of data from six randomized, placebo-control trials showed that
improvement rate in mild, moderate, and severe ED after taking
tadalaﬁl 5 mg once daily was 74.8%, 63.1%, and 44.5%, respec-
tively.36 The response rate in men with ED showed no signiﬁcant
difference between tadalaﬁl on demand and once daily; however, a
lower incidence of treatment-emergent adverse events ( 4%) was
reported for tadalaﬁl once daily because of a lower peak plasma
concentration than on demand.37,38 The differences in clinical effect
of PDE5 inhibitors administered on demand or daily for the treat-
ment of ED are compared in Table 3.7. New clinical indications
According to the classiﬁcation of theWorld Health Organization,
pulmonary hypertension has ﬁve classes: idiopathic pulmonary
arterial hypertension (PAH) and the remaining four groups with
different etiologies. Patients with PAH have two important features
in the pulmonary vasculature: increased expression of the vaso-
constrictor PDE5 and decreased production of the vasodilator NO.39
An illustrative trial (SUPER-1 trial)40 and an open-label 3-year
extension trial (SUPER-2 trial)41 established the efﬁcacy of sildena-
ﬁl in the treatment of PAH. Compared with placebo, sildenaﬁl
improved 6-minute walking distance, mean pulmonary artery
pressure, and functional class in adose-dependent fashion. The FDA-
recommendeddose for sildenaﬁl for treatmentof PAH is 20mg three
times daily. Tadalaﬁl also demonstrated its clinical improvement in
PAH in the PHIRST-142 and -243 trials. The FDA-recommended dose
for treatment of PAH is tadalaﬁl 40 mg daily. Vardenaﬁl is not
approved by the FDA for the treatment of PAH, although clinical
improvement was also demonstrated in the trial.44
Altitude sickness consists of three syndromes: acute mountain
sickness, high-altitude cerebral edema, and high-altitude pulmo-
nary edema (HAPE). HAPE usually occurs at altitudes > 3000 m in
rapidly ascending nonacclimatized individuals within the ﬁrst
2e5 days after arrival.45 The prevalence of HAPE depends on the
degree of susceptibility, rate of ascent, and ﬁnal altitude. Rapid
ascent is the most important and modiﬁable risk factor. HAPE is the
leading cause of death from altitude sickness, but can be prevented
by careful ascent and reversed with early recognition and treat-
ment. Placebo-controlled trials conﬁrmed that taking sildenaﬁl or
tadalaﬁl can signiﬁcantly reduce the incidence of HAPE.46,47 PDE5
inhibitors (sildenaﬁl and tadalaﬁl) have been shown to be effective
and safe in the treatment and prevention of HAPE.48and or daily for treatment of erectile dysfunction.
tion Once daily administration
Spontaneity, no time frame
es Appropriate for men with high sexual frequency
Lower
May not be enough for men who are considered difﬁcult to treat
Higher
Constant
B.-P. Jiann / Urological Science 27 (2016) 66e70 69ED and lower urinary tract symptoms (LUTSs) secondary to
benign prostatic hyperplasia (BPH) are commonmedical diseases in
men older than 50 years. Epidemiological studies suggest there is a
strong correlation between both of them.49 mRNA expression for
PDE5 has been demonstrated in rat lower urinary tract tissue.50
Sildenaﬁl, tadalaﬁl, and vardenaﬁl dose-dependently reduced
contraction of isolated bladder and urethral and prostate strips in
animal studies,50 and clinical studies showed improvement in
LUTSs.51 Nevertheless, only tadalaﬁl 5 mg once daily is approved for
the treatment of LUTSs secondary to BPH with or without ED. An
integrated analysis of pooled data from four randomized, placebo-
controlled tadalaﬁl clinical studies demonstrated that signiﬁcant
improvement in ED (assessed by the IIEF) and LUTSs [assessed by
the International Prostate Symptom Score (IPSS)] were conﬁrmed
regardless of baseline severity and improvements in the total IPSS
and the IIEF-Erectile Function domain score were weakly corre-
lated.52 Combined use of PDE5 inhibitor and a-blockers provided
additive favorable effects in symptomatic relief compared with
PDE5 inhibitor monotherapy.53 Long-term results for combination
of tadalaﬁl with a-blockers for the treatment of ED and BPH in men
is still lacking. Prescribing daily PDE5 inhibitors for the treatment of
LUTSs secondary to BPH faces a major challenge of cost-
effectiveness compared with a-blockers in clinical practice.
8. Conclusions
PDE5 inhibitor is the most popular form for treatment of ED.
More new PDE5 inhibitors, new preparation methods of agents and
daily dosing provide more ﬂexibility in clinical treatment for ED
patients and physicians. Moreover, the clinical indications of PDE5
inhibitors have extended from ED to PAH and LUTSs secondary to
BPH. Possible future indications for versatile PDE5 inhibitors are
still developing that may provide new solutions for diseases in the
future.
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